Dr. Mike Montalto, PhD, PathAI Chief Scientific Officer, explores the potential of artificial intelligence to standardize the analysis of tumor microenvironment (TME) which will enable researchers to better understand treatment pathways, identify novel biomarkers, and advance drug development. Mike Montalto
Get In Touch
PathAI Media
Company Contact
Liz Storti
Chief People Officer
Media Contact
Daniel Donato
LifeSci Communications
516-474-0554